{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:22:44Z","timestamp":1788542564612,"version":"build-2803163510"},"reference-count":20,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1242,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[1998,8]]},"abstract":"<jats:sec><jats:title>Aim:<\/jats:title><jats:p>To compare the efficacy and tolerability of olsalazine sodium with enteric\u2010coated mesalazine in inducing endoscopic remission in patients with mild to moderate active ulcerative colitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods:<\/jats:title><jats:p>Patients with mild to moderate active ulcerative colitis were randomized to receive either olsalazine sodium, 3\u2003g\/day (<jats:italic>n<\/jats:italic>\u2003=\u200388), or mesalazine, 3\u2003g\/day (<jats:italic>n<\/jats:italic>\u2003=\u200380), for up to 12\u2003weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Of the patients treated with olsalazine sodium, 52.2% achieved endoscopic remission, compared with 48.8% of patients treated with mesalazine. This difference was not significant (<jats:italic>P\u2003<\/jats:italic>=\u20030.67). There was a non\u2010significant trend for patients with left\u2010sided colitis or a more severe endoscopic grade to achieve remission if they were treated with olsalazine sodium than if they were treated with mesalazine. Both treatments were comparable with respect to clinical activity index and an investigator\u2019s global assessment. Seventy patients reported one or more adverse events; adverse events were seen in 45% of olsalazine sodium\u2010treated patients and in 36% of mesalazine\u2010treated patients. Eleven patients treated with olsalazine sodium and nine patients treated with mesalazine withdrew from the study because of adverse events. One patient treated with olsalazine sodium compared with two treated with mesalazine stopped treatment because of diarrhoea. Serious adverse events occurred in three patients treated with olsalazine sodium and in four treated with mesalazine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Therapeutic effectiveness and tolerance to the treatment did not differ between olsalazine sodium, 3\u2003g\/day, and mesalazine, 3\u2003g\/day, in inducing endoscopic remission in patients with mild to moderate active ulcerative colitis within 12\u2003weeks of treatment.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.1998.00360.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:37:08Z","timestamp":1047353828000},"page":"707-715","source":"Crossref","is-referenced-by-count":49,"title":["Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis"],"prefix":"10.1111","volume":"12","author":[{"family":"Kruis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Brandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Theuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Krakamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Lorenz\u2010Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Judmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0889-8553(21)00053-4","article-title":"Sulfasalzine and 5\u2010ASA compounds","volume":"21","author":"Allgayer H","year":"1992","journal-title":"Gastroenterol Clin North Am"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.28.2.196"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528809101546"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.30.5.675"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.30.10.1354"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528809101553"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1986.tb00121.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(87)90253-8"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.291.6506.1373"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1987.tb00627.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.298.6666.82"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(82)90024-1"},{"key":"e_1_2_6_14_2","unstructured":"ICH Topic E9.Statistical principles for clinical trials step 3 draft. 17\u2003January 1997."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91601-4"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.31.11.1271"},{"key":"e_1_2_6_17_2","first-page":"1188","article-title":"Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial","volume":"88","author":"Hanauer S","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712243172603"},{"key":"e_1_2_6_19_2","first-page":"155","article-title":"Towards an optimal dosage of oral 5\u2010ASA in ulcerative colitis","volume":"5","author":"De Dombal FT","year":"1992","journal-title":"Gastroenterol Int"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(86)90882-6"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.29.6.835"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1998.00360.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1998.00360.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.1998.00360.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T06:59:05Z","timestamp":1694415545000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.1998.00360.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[1998,8]]}},"alternative-id":["10.1046\/j.1365-2036.1998.00360.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.1998.00360.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,8]]}}}